Drug maker Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat certain eye conditions.
The company has received approval from the US Food and Drug Administration to market Etabonate Ophthalmic Suspension, the Mumbai-based drug maker said in a statement.
The company's product is the generic equivalent of Bausch & Lomb Inc's Lotemax ophthalmic suspension (0.5%), it added.
Loteprednol Etabonate ophthalmic suspension, 0.5%, is indicated for temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.
As per the IQVIA MAT data, the product had estimated annual sales of USD 59 million in the US.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
